This study is an Open-Label, Phase 1/2a, First-in-Human, Dose-Escalation, Dose-Expansion, and Proof-of-Concept Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of DA-4505 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors.
Aged 18 and older.
Capable of giving signed informed consent.
Diagnosed with particular disease characteristics.
Expected survival ≥ 3 months.
Inability to take oral medications or gastrointestinal abnormalities potentially impacting absorption.
Current enrollment or past participation in another clinical trial.
Unresolved adverse reactions (except alopecia) from previous cancer-directed therapy.
Use of cancer-directed therapies, including chimeric antigen receptor T cell therapy.